Dale, Trevor http://orcid.org/0000-0002-4880-9963
Clarke, Paul A http://orcid.org/0000-0001-9342-1290
Esdar, Christina
Waalboer, Dennis
Adeniji-Popoola, Olajumoke
Ortiz-Ruiz, Maria-Jesus
Mallinger, Aurélie
Samant, Rahul S http://orcid.org/0000-0003-1952-259X
Czodrowski, Paul
Musil, Djordje
Schwarz, Daniel
Schneider, Klaus
Stubbs, Mark
Ewan, Ken
Fraser, Elizabeth
TePoele, Robert
Court, Will
Box, Gary
Valenti, Melanie
de Haven Brandon, Alexis
Gowan, Sharon
Rohdich, Felix
Raynaud, Florence
Schneider, Richard
Poeschke, Oliver
Blaukat, Andree
Workman, Paul
Schiemann, Kai
Eccles, Suzanne A
Wienke, Dirk
Blagg, Julian
Article History
Received: 8 April 2015
Accepted: 1 October 2015
First Online: 26 October 2015
Competing interests
: T.D., P.A.C., W.C., D.W., O.A.P., M.O.R., A.M., R.S.S., M.S., E.F., R.T.P., A.H.B., M.V., G.B., S.G., F. Raynaud, P.W., S.A.E. and J.B. are current or former employees of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors. C.E., P.C., F. Rohdich, D.M., K. Schiemann, K. Schneider, D.S., R.S., O.P., A.B. and D.W. are current or former employees of Merck Serono, which has a commercial interest in the development of WNT pathway inhibitors.